2エチニルベンザルデヒド基,ライシン標的のタンパク質キナーゼおよびノンキナーゼの不可逆的共性阻害剤
Peng Chen1, Guanghui Tang2, Chengjun Zhu3
1School of Pharmaceutical Sciences (Shenzhen), Sun Yat-sen University, Shenzhen 518107, China.
Journal of the American Chemical Society
|February 12, 2023
まとめ
この研究は,選択的,細胞活性ライシン標的の不可逆的共性阻害剤の作成のための新しい2エチニルベンザルデヒド (EBA) ベースの戦略を導入します. このアプローチは,ABLキナーゼ,EGFR,Mcl-1に対する強力な阻害剤を成功裏に生成し,広範な適用性を示した.
科学分野:
- 薬剤化学
- 化学生物学
- 薬物の発見
背景:
- リシンを標的とする不可逆的共性阻害剤は,特にキナーゼの研究において,関心を得ています.
- 選択的,細胞活性ライシンターゲティング阻害剤の既存の化学成分は限られている.
- 保存された触媒性ライシンをターゲットにすると,強力で選択的な抑制への経路が提供されます.
研究 の 目的:
- リジン標的の不可逆的共性阻害剤のための新しい2エチニルベンザルデヒド (EBA) ベースの戦略を開発する.
- ABLキナーゼに対する強力で選択的な小分子阻害剤を生成する.
- EGFRとMcl-1のような他のターゲットに対して,EBA戦略の一般性を検証する.
主な方法:
- 2-エチニルベンザルデヒド (EBA) ベースの小分子設計と合成
- 抑制剤の効能,選択性,細胞活動の評価
- 細胞内の標的タンパク質 (ABL,EGFR,Mcl-1) との共性結合の評価
- 対象外効果と滞在時間の分析
主要な成果:
- EBAベースの阻害剤は,ABLキナーゼの触媒性ライシンを標的とした強力な選択的阻害を示した.
- 化合物は細胞活性で,K562細胞における内生ABLキナーゼを共性的に誘導し,長期間存在していた.
- この戦略は,EGFR (キナーゼ) とMcl-1 (非キナーゼ) の阻害剤を製造するために一般化され,触媒性および非触媒性ライシンの両方を標的とした.
- ミニマルオフターゲットのエンゲージメントが観察されました.
結論:
- 2エチニルベンザルデヒド (EBA) ベースの戦略は,選択的,ライシン標的の不可逆的共性阻害剤の開発のための汎用的なプラットフォームを提供します.
- このアプローチは,キナーゼと非キナーゼを含む多様な生物学的標的に対する強力な細胞活性阻害剤の生成を可能にします.
- 開発された阻害剤は長期滞在時間や標的の選択性などの好ましい性質を示し,新しい治療戦略の道を開いています.
関連する概念動画
Enzyme Inhibition
78.9K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.9K
Ligand Binding and Linkage
4.8K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
4.8K
Transducer Mechanism: Enzyme-Linked Receptors
2.6K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.6K
Covalently Linked Protein Regulators
6.9K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.9K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
Targets for Drug Action: Overview
6.8K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.8K


